Who Should Bear the Cost of Orphan Drugs?

Sometimes called “living drugs,” Cell and Gene Therapies have the potential to cure an individual of a rare disease by modifying that person’s genes. But due to the labor-intensive, individualized treatment, these drugs are expensive, to the tune of millions of dollars per patient.

Rena Conti, BU Questrom associate professor of markets, public policy, and law; U.S. Rep. Jake Auchincloss (D-Mass.); Michael Sherman, RA Capital Management venture partner; and Andrew Obenshain, biotech company Bluebird Bio CEO, discuss how to ensure continued innovation and access to gene and cell therapy without breaking the bank.

Learn more about your ad choices. Visit podcastchoices.com/adchoices